Redox cofactor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Purified NAD+ is typically supplied as a white to off-white powder and stored desiccated at low temperature. Airtight containers limit moisture uptake, while protection from light reduces degradation of the nicotinamide ring. Aqueous stock solutions are less stable than solid material and are often aliquoted before freezing. Repeated freeze-thaw cycles can lower integrity, so working portions are kept separate. Purity is commonly checked by ultraviolet absorbance near 260 nm, high-performance liquid chromatography, or mass spectrometry.
Stability studies show that NAD+ can hydrolyze under prolonged heat, extreme pH, or microbial contamination. Phosphate buffers near neutral pH are often used for short-term handling, though exact stability depends on concentration, temperature, and matrix. In biological samples, endogenous enzymes can rapidly degrade NAD+, making cold chain and fast processing important. Analytical reports should state extraction conditions, internal standards, and validation parameters. Without those details, comparisons across studies remain difficult and potentially misleading.
Nicotinamide adenine dinucleotide, abbreviated NAD+, is a dinucleotide built from adenine, nicotinamide, two ribose sugars, and two phosphate groups. The oxidized form carries a positive charge on the nicotinamide ring, while the reduced form, NADH, is neutral. This pair acts as a reversible electron carrier in cells. NAD+ is present in bacteria, plants, animals, and fungi. Its structure allows it to accept and donate electrons without being consumed in the reactions it supports.
In redox reactions, NAD+ accepts a hydride ion, which consists of two electrons and one proton. The hydride adds to the nicotinamide ring at a specific carbon, converting NAD+ into NADH. Dehydrogenase enzymes use this step in glycolysis, the citric acid cycle, and fatty acid oxidation. NADH later donates electrons to the mitochondrial electron transport chain, helping to drive ATP synthesis. The balance between NAD+ and NADH reflects the metabolic state of a cell, and shifts in that balance can alter how pathways operate.
Beyond electron transfer, NAD+ serves as a substrate for enzymes that cleave it and attach its ADP-ribose portion to other molecules. This group includes poly(ADP-ribose) polymerases, CD38, and sirtuins. Such reactions consume NAD+ and can influence its availability for metabolism. Cells replenish NAD+ through a salvage pathway that recycles nicotinamide and through routes starting from tryptophan or vitamin B3 forms. How these synthesis and consumption routes are coordinated across tissues remains an active area of study, and compartment-specific concentrations are difficult to measure directly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized or precipitated solid |
| Solubility | Water-soluble | Also soluble in aqueous buffers; limited in nonpolar solvents |
| Typical storage | -20 °C, desiccated | Short-term solutions may be kept at 2-8 °C |
| Common analytical method | HPLC with UV detection | LC-MS provides additional confirmation |
| Stability risk | Hydrolysis | Accelerated by heat, extreme pH, and repeated freeze-thaw |
Quantification of NAD+ in biological samples typically uses liquid chromatography coupled to mass spectrometry. Enzymatic cycling assays offer higher throughput and rely on NAD+ dependent dehydrogenases to amplify signal. Both approaches require careful sample quenching because NAD+ can be rapidly consumed or converted after collection. Acidic extraction is common for NAD+, while alkaline conditions favor NADH in some protocols. Isotopically labeled internal standards help correct for losses during extraction and ionization.
Commercial NAD+ is available at research grade, often with purity specifications determined by high-performance liquid chromatography. Certificates of analysis may report water content, residual solvents, and counterion identity. Identity can be confirmed by ultraviolet absorbance near 260 nm, mass spectrometry, or enzymatic activity. Because different salt forms and hydration states exist, researchers should verify that the product matches the intended molecular form. Lot-to-lot variation in purity can affect quantitative assays and should be documented.
Solid NAD+ is usually supplied as a white to off-white powder or lyophilized preparation. It is hygroscopic and should be kept desiccated at low temperature, commonly -20 °C or below for long-term storage. Aqueous solutions are less stable than dry material and are often prepared fresh or stored frozen in aliquots. Light exposure and repeated freeze-thaw cycles can promote degradation, so amber containers and single-use aliquots are preferred. Buffered solutions near neutral pH are generally less stable than acidic or frozen preparations.
NAD+ is a dinucleotide composed of two nucleotides joined by a pyrophosphate linkage. One nucleotide contains adenine, and the other contains nicotinamide. The oxidized form carries a positive charge on the nicotinamide ring and is abbreviated NAD+. It functions as a cofactor in hydride-transfer reactions, accepting electrons in catabolic pathways. In cells, it interconverts with reduced NADH, forming a redox couple central to energy metabolism. The molecule is water-soluble and does not cross cell membranes freely without specific transport or precursor pathways.
The nicotinamide ring undergoes reversible reduction at the para position, converting NAD+ to NADH. This reaction transfers a hydride equivalent, not a free hydrogen atom or electron alone. Because the redox pair has a defined reduction potential, it links oxidation of fuels to respiratory chain activity. Many dehydrogenases use NAD+ as a co-substrate and produce NADH. The ratio of NAD+ to NADH reflects metabolic state and influences flux through several pathways.
NAD+ also serves as a substrate for enzymes that cleave it, including sirtuins, PARPs, and CD38. These enzymes consume NAD+ and release nicotinamide and ADP-ribose or related products. The dual roles as redox cofactor and signaling substrate connect NAD+ to DNA repair, circadian regulation, and calcium signaling. Cellular NAD+ concentrations vary by tissue, time of day, and stress exposure. How these consumption pathways interact with redox balance remains an active area of research.
=== Cardiac rhythm disease management === Cardiac rhythm disease management (CRDM) is the oldest and largest of Medtronic's business units. Its work in heart rhythm therapies dates back to 1957 when Bakken developed the first wearable heart pacemaker to treat abnormally slow heart rates. Since then, it has expanded its expertise in electrical stimulation to treat other cardiac rhythm diseases. It has also made an effort to address overall disease management by adding diagnostic and monitoring capabilities to many of its devices. An independently-operating Dutch pacemaker manufacturer, Vitatron, acquired by Medtronic in 1986, is now a European subsidiary of the unit. Medtronic and Vitatron pacemakers are interrogated and programmed by Medtronic Carelink Model 2090 Programmer for Medtronic and Vitatron Devices; they use separate interfaces. In 2007, Medtronic recalled its Sprint Fidelis product, the flexible wires, or leads, which connect a defibrillator to the interior of the heart. The leads were found to be failing at an unacceptable rate, resulting in unnecessary shocks or no shocks when needed; either can be lethal. The scope of the problem continues to be a matter of research. Studies since the recall, disputed by Medtronic, suggest that the failure rate of already-implanted Sprint Fidelis leads is increasing exponentially. Medtronic's liability is limited by various court decisions.
== Biography == Robert Brownlee was born October 21, 1942, in South Dakota. He founded Brownlee Labs in the 1970s, in the San Francisco Bay area, a manufacturer of columns and pumps for high-performance liquid chromatography systems. Bob Brownlee took the initiative "along with Tom Jupille, Steve Bakalyar, Nelson Cooke, Jerry Higgins and Ron Majors" to form the Bay Area Chromatography Colloquium. Bob Stevenson is quoted as saying in his Nine Lives of the California Separation Science Society that Brownlee Labs was "certainly one of the globe's leaders in HPLC column technology." In the 1980s, when Robert Brownlee was diagnosed with AIDS-related complex, he sold his company to Applied Biosystems of Foster City, California, in 1984. (Applied later merged with Perkin-Elmer). Sometime later, he began a new company, which was viewed by Applied as a competitor. A lawsuit was instituted and later settled (Brownlee v. Applied Biosystems, Inc., 1989-1 Trade Cas. (CCH) ¶ 68, (N.D. Cal. 1989) 8,14). In 1990, he was interviewed for an article in The Scientist about Applied Biosystems. "If you produce the first product for these virgins [scientists without such equipment], you have a big value added, and you can charge a big price for your product," Brownlee says. "That's the reason Applied Biosystems did so well." He also formed the Robert Brownlee Foundation, a private family foundation which supports, with grants, K–12 science.
== Mechanism of action == Melanotan II acts as a non-selective agonist of the melanocortin receptors MC1, MC3, MC4, and MC5. Melanotan II produces melanogenesis by activation of the MC1 receptor, whereas its clinically documented sexual effects are thought to be related to its ability to activate the MC4 receptor (though the MC3 is thought to also possibly be involved). Melanotan II is partly metabolised into Bremelanotide, a medication used to treat low sexual desire. Other effects of melanotan II, mostly regarded as adverse effects, include flushing, nausea, vomiting, stretching, yawning, and loss of appetite (the last via activation of MC4).
Sources: en.wikipedia.org
In July 2009, there were a series of coordinated denial of service attacks against major government, news media, and financial websites in South Korea and the United States. While many thought the attack was directed by North Korea, one researcher traced the attacks to the United Kingdom. Security researcher Chris Kubecka presented evidence multiple European Union and United Kingdom companies unwittingly helped attack South Korea due to a W32.Dozer infections, malware used in part of the attack. Some of the companies used in the attack were partially owned by several governments, further complicating cyber attribution. In July 2011, the South Korean company SK Communications was hacked, resulting in the theft of the personal details (including names, phone numbers, home and email addresses and resident registration numbers) of up to 35 million people. A trojaned software update was used to gain access to the SK Communications network. Links exist between this hack and other malicious activity and it is believed to be part of a broader, concerted hacking effort. With ongoing tensions on the Korean Peninsula, South Korea's defense ministry stated that South Korea was going to improve cyber-defense strategies in hopes of preparing itself from possible cyber attacks. In March 2013, South Korea's major banks – Shinhan Bank, Woori Bank and NongHyup Bank – as well as many broadcasting stations – KBS, YTN and MBC – were hacked and more than 30,000 computers were affected; it is one of the biggest attacks South Korea has faced in years.
Nobel Prize in Physiology or Medicine (1929) Bernard Horecker (1914–2010). American biochemist at Cornell University known for elucidation of the pentose phosphate pathway. Member Natl. Acad. Sci. USA. Linda Hsieh-Wilson (PhD 1996). American chemist known for work in chemical neurobiology and the structure and function of carbohydrates in the nervous system Wayne L. Hubbell (b. 1943). American biochemist at UCLA, pioneer of site-directed spin labelling. Member Natl. Acad. Sci. USA. Hugh Huxley (1924–2013). British molecular biologist at University College London and Brandeis University noted for discovery the underlying principle of muscle movement.
== Further reading == Epstein, Noah; Chandran, Sheena; Chou, Loretta (2012). "Current Concepts Review: Intra-Articular Fractures of the Calcaneus". Foot & Ankle International. 33 (1): 79–86. doi:10.3113/FAI.2012.0079. ISSN 1071-1007. McKinley, Todd O; Borrelli, Joseph; D'Lima, Darryl D; Furman, Bridgette D; Giannoudis, Peter V (2010). "Basic Science of Intra-articular Fractures and Posttraumatic Osteoarthritis". Journal of Orthopaedic Trauma. 24 (9). Ovid Technologies (Wolters Kluwer Health): 567–570. doi:10.1097/bot.0b013e3181ed298d. ISSN 0890-5339. PMC 3662545.
The active components of an RNA-induced silencing complex (RISC) are endonucleases called Argonaute proteins, which cleave the target mRNA strand complementary to their bound siRNA. As the fragments produced by Dicer are double-stranded, they could each in theory produce a functional siRNA. However, only one of the two strands, which is known as the guide strand, binds Argonaute and directs gene silencing. The other anti-guide strand or passenger strand is degraded during RISC activation. Although it was first believed that an ATP-dependent helicase separated these two strands, the process proved to be ATP-independent and performed directly by the protein components of RISC. However, an in vitro kinetic analysis of RNAi in the presence and absence of ATP showed that ATP may be required to unwind and remove the cleaved mRNA strand from the RISC complex after catalysis. The guide strand tends to be the one whose 5′ end is less stably paired to its complement, but strand selection is unaffected by the direction in which Dicer cleaves the dsRNA before RISC incorporation. Instead, the R2D2 protein may serve as the differentiating factor by binding the more-stable 5′ end of the passenger strand. The structural basis for binding of RNA to the Argonaute protein was examined by X-ray crystallography of the binding domain of an RNA-bound Argonaute.
Sources: en.wikipedia.org
Many enzymes consume or produce NAD+ within seconds after a sample is collected. Quenching stops those reactions and helps preserve the ratio between oxidized and reduced forms. The exact quenching method depends on the tissue or cell type and the analytes of interest.
NAD+ is present in blood cells, but plasma measurements are complicated by release from cells during processing. Careful collection and immediate separation of cellular components are required. Researchers often prefer specific cell or tissue samples to answer questions about NAD+ pools.
Solid NAD+ is dissolved in suitable aqueous buffer, often near neutral pH, and kept cold. Solutions are typically aliquoted to avoid repeated freeze-thaw cycles. Protection from light and microbial contamination supports stability during storage.
It indicates the oxidized form, which has a positive charge on the nicotinamide nitrogen. The reduced partner NADH lacks that charge and carries added electrons. The plus sign is part of the standard abbreviation, not a separate ion.